European HIV Vaccine Alliance (EHVA): An EU Platform for the Discovery and Evaluation of Novel Prophylactic and Therapeutic Vaccine Candidates
ipal Investigator: Prof. Yves Levy
Baylor Principal Investigator: Gerard Zurawski, PhD
Funding Organization: European Commission
Project Start: 2015
Project End: 2020
The European HIV Vaccine Alliance (EHVA) program has as major goal to develop a Multidisciplinary Vaccine Platform (MVP) in the fields of prophylactic and therapeutic HIV vaccines. The MVP includes four components: 1) Discovery, 2) Immune Profiling, 3) Data Management, Integration and Down-Selection, and 4) Clinical Trials. This will be achieved by bringing together, within a highly-integrated and ambitious 5-year European program, internationally recognized experts from both public/academic and private sectors in the fields of immunology, virology, structural biology, viral vectors, statistics and computational science and clinical science. EHVA will also contribute to the field of HIV vaccines with a portfolio of highly-promising vaccine candidates that will be optimized and tested via the EHVA platform so as to be moved into larger clinical trials through EDCTP.